182 related articles for article (PubMed ID: 30974024)
1. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Sharma ND; Nickl CK; Kang H; Ornatowski W; Brown R; Ness SA; Loh ML; Mullighan CG; Winter SS; Hunger SP; Cannon JL; Matlawska-Wasowska K
Cancer Sci; 2019 Jun; 110(6):1931-1946. PubMed ID: 30974024
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
3. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
[TBL] [Abstract][Full Text] [Related]
4. Multiomics to investigate the mechanisms contributing to repression of PTPRC and SOCS2 in pediatric T-ALL: Focus on miR-363-3p and promoter methylation.
Drobna-Śledzińska M; Maćkowska-Maślak N; Jaksik R; Kosmalska M; Szarzyńska B; Lejman M; Sędek Ł; Szczepański T; Taghon T; Van Vlierberghe P; Witt M; Dawidowska M
Genes Chromosomes Cancer; 2022 Dec; 61(12):720-733. PubMed ID: 35778917
[TBL] [Abstract][Full Text] [Related]
5. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.
Porcu M; Kleppe M; Gianfelici V; Geerdens E; De Keersmaecker K; Tartaglia M; Foà R; Soulier J; Cauwelier B; Uyttebroeck A; Macintyre E; Vandenberghe P; Asnafi V; Cools J
Blood; 2012 May; 119(19):4476-9. PubMed ID: 22438252
[TBL] [Abstract][Full Text] [Related]
6. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling.
Collins AS; McCoy CE; Lloyd AT; O'Farrelly C; Stevenson NJ
PLoS One; 2013; 8(7):e69090. PubMed ID: 23894411
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
8. lncRNA HAND2-AS1 Inhibits Liver Cancer Cell Proliferation and Migration by Upregulating SOCS5 to Inactivate the JAK-STAT Pathway.
Yan D; Jin F; Lin Y
Cancer Biother Radiopharm; 2020 Mar; 35(2):143-152. PubMed ID: 32155348
[No Abstract] [Full Text] [Related]
9. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia.
Teramo A; Gattazzo C; Passeri F; Lico A; Tasca G; Cabrelle A; Martini V; Frezzato F; Trimarco V; Ave E; Boscaro E; Piazza F; Facco M; Trentin L; Semenzato G; Zambello R
Blood; 2013 May; 121(19):3843-54, S1. PubMed ID: 23515927
[TBL] [Abstract][Full Text] [Related]
10. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
11. SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
Lahera A; López-Nieva P; Alarcón H; Marín-Rubio JL; Cobos-Fernández MÁ; Fernández-Navarro P; Fernández AF; Vela-Martín L; Sastre I; Ruiz-García S; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Br J Haematol; 2023 May; 201(4):718-724. PubMed ID: 36786170
[TBL] [Abstract][Full Text] [Related]
12. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C; Schwab C; Broux M; Geerdens E; Degryse S; Demeyer S; Lahortiga I; Elliott A; Chilton L; La Starza R; Mecucci C; Vandenberghe P; Goulden N; Vora A; Moorman AV; Soulier J; Harrison CJ; Clappier E; Cools J
Haematologica; 2015 Oct; 100(10):1301-10. PubMed ID: 26206799
[TBL] [Abstract][Full Text] [Related]
13. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
14. SOCS3 and SOCS5 mRNA expressions may predict initial steroid response in nephrotic syndrome children.
Ostalska-Nowicka D; Smiech M; Jaroniec M; Zaorska K; Zawierucha P; Szaflarski W; Malinska A; Nowicki M
Folia Histochem Cytobiol; 2011; 49(4):719-28. PubMed ID: 22252769
[TBL] [Abstract][Full Text] [Related]
15. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
16. The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy.
Tao W; Wen F; Zhang H; Liu G
Brain Dev; 2009 Mar; 31(3):200-7. PubMed ID: 18715729
[TBL] [Abstract][Full Text] [Related]
17. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma.
Kleppe M; Tousseyn T; Geissinger E; Kalender Atak Z; Aerts S; Rosenwald A; Wlodarska I; Cools J
Haematologica; 2011 Nov; 96(11):1723-7. PubMed ID: 21791476
[TBL] [Abstract][Full Text] [Related]
19. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
20. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
